Key Takeaways
- Abbott delivered Q1 EPS of $1.15, in line with analyst projections ranging from $1.14 to $1.15
- Quarterly revenue reached $11.16B, surpassing the $11B Wall Street consensus
- The recently acquired cancer diagnostics division from Exact Sciences contributed significantly to performance
- The medical device segment, Abbott’s primary revenue generator, maintained strong momentum
- Second quarter EPS forecast of $1.25–$1.31 trails analyst expectations of $1.32
Abbott Laboratories unveiled its first-quarter financial performance on April 16, delivering revenue figures that exceeded analyst projections, with meaningful contributions from its recently integrated cancer diagnostics operations.
The healthcare giant posted adjusted earnings per share of $1.15 for the three-month period. This figure aligned with one analyst estimate of $1.15 and exceeded another consensus forecast of $1.14 by a single cent, varying by data provider.
Quarterly revenue totaled $11.16 billion, comfortably exceeding Wall Street’s $11 billion projection.
Shares concluded trading at $101.56 prior to the earnings announcement. ABT has declined 16.59% during the previous three-month period and has dropped 22.46% year-over-year.
The Exact Sciences transaction significantly influenced this quarter’s financial results. Abbott reached an agreement to acquire the cancer diagnostics specialist in November at $105 per share, representing a transaction value of approximately $23 billion. The acquisition finalized in March 2026.
This transaction represents among Abbott’s most substantial acquisitions and signals its strategic entry into oncology diagnostics. The newly integrated division’s performance contributed meaningfully to the Q1 revenue outperformance.
Medical Device Segment Maintains Momentum
Abbott’s medical device division continues as its largest revenue contributor. The segment delivered solid results in Q1, providing essential support for the overall revenue beat.
The healthcare company has consistently relied on its device operations as a fundamental revenue engine across recent quarters. This pattern persisted throughout the opening quarter of 2026.
Forward Guidance Trails Street Expectations
Looking ahead to Q2 2026, Abbott projected EPS between $1.25 and $1.31. Analyst consensus stood at $1.32, positioning Abbott’s guidance midpoint marginally below Wall Street’s forecast.
For fiscal year 2026, Abbott anticipates EPS ranging from $5.38 to $5.58. The analyst consensus of $5.47 lands within this guided range.
Over the past 90 days, Abbott has received zero upward EPS estimate revisions and 18 downward revisions. This represents a decline from the previous quarter’s “great performance” financial health assessment — InvestingPro currently assigns Abbott a “good performance” financial health rating.
The revenue outperformance provides some confidence, despite guidance falling short of full Street expectations. Abbott’s Q1 top-line execution emerged as the stronger element of this earnings report.
The full-year EPS consensus of $5.47 remains comfortably within Abbott’s projected range of $5.38 to $5.58, providing the company latitude to meet or exceed that benchmark as fiscal 2026 progresses.
